ArticleBone marrow transplantation2006
Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma.
Article in Bone marrow transplantation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review.Frontiers in oncology · 2023Pooled it
- Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Trial
- Trial
- Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.Bone marrow transplantation · 2009Trial
- The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma.Leukemia & lymphoma · 2022Article
- Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy.International journal of hematology · 2020Article
- Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort.ACR open rheumatology · 2019Article
- B- and T-lymphocyte number and function in HIVScientific reports · 2016Article
- Secondary antibody deficiency - causes and approach to diagnosis.Clinical medicine (London, England) · 2016Article
- Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.Oncotarget · 2016Article
- A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.Oncotarget · 2016Article
- Review
- Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.Haematologica · 2014Article
- Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.Frontiers in immunology · 2014Review
- Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement.PloS one · 2014Article
- CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Article
- Central nervous system involvement of epstein barr virus associated lymphoproliferative disorder in a child with acute lymphoblastic leukemia: successful treatment with rituximab and interferon-alpha.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2013Article
- Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.Current opinion in oncology · 2012Review
- Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.Journal of gastroenterology · 2011Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab is an anti-CD20 monoclonal antibody that has efficacy in B-cell non-Hodgkin's lymphoma (NHL). Adjuvant immunotherapy with rituximab may reduce relapse rates for high-risk B-cell NHL following high-dose chemotherapy with autologous stem cell transplantation (SCT). However, the potential adverse effects of rituximab on immune reconstitution following SCT are not fully characterized. We performed a retrospective analysis of immunoglobulin (Ig) levels and peripheral blood neutrophil counts in 11 patients who received adjuvant rituximab following autologous SCT for B-cell NHL. Results were compared to a contemporaneous group of 24 patients who received an identical conditioning regimen and autologous SCT for lymphoma, but no adjuvant rituximab. Adjuvant rituximab was associated with a significantly increased incidence of hypogammaglobulinaemia between 12 and 24 months post-SCT, but not neutropenia. Despite suppression of Igs, there were no late or atypical infective complications attributable to rituximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.